Publikation

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE).

Wissenschaftlicher Artikel/Review - 15.07.2022

Bereiche
PubMed
DOI
Kontakt

Zitation
Sudano I, Mach F, Moccetti T, Burkard T, Fahe C, Delabays A, Rickli H, Keller P, Dopheide J, Bodenmann S, Fiolka T, Ehret G, Spirk D. Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE). Front Cardiovasc Med 2022; 9:953040.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Front Cardiovasc Med 2022; 9
Veröffentlichungsdatum
15.07.2022
ISSN (Druck)
2297-055X
Seiten
953040
Kurzbeschreibung/Zielsetzung

Low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). In confirmatory trials, proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab substantially lowered LDL-C and reduced cardiovascular morbidity and mortality. However, the routine clinical use of alirocumab in Switzerland has not yet been studied.